Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Europe

Set Alert for Europe

EU Crunch Time For Mirikizumab, New Covid-19 Vaccine & Other Drugs

The European Medicines Agency’s human medicines committee, the CHMP, is this week deciding whether to back marketing approval for eight new drugs and a coronavirus vaccine.

Europe Drug Review

European Commission Steps In To Address Drug Trial Delays Due To IVD Regulation

The commission is in talks with EU member states to identify possible regulatory bottlenecks in the approval of combined clinical trials for a medicinal product and a clinical performance study of an IVD.

Europe Clinical Trials

EMA Report Highlights Parallel Regulatory/HTA Consultations Among Achievements

A report from the EMA summarizing the mid-term achievements of its Regulatory Science Strategy to 2025 covers health technology assessments and a range of other topics.

Europe Cost Effectiveness

EU Review Proposals ‘Fail To Analyze’ Impact Of Reduced Exclusivity Periods

Plans for the overhaul of the EU’s medicines framework are missing key analysis on the effect of reductions in data and market protection on the pharmaceutical industry, despite an abundance of studies on how such incentives influence company decisions on whether to develop new products, say lawyers from Sidley.

Europe Intellectual Property

EU Guide Outlines Important Considerations For Submitting Complex Trials In CTIS

EU regulators have issued a new Q&A document on the key aspects that sponsors of complex trials should consider when making new submissions or moving ongoing studies to the Clinical Trials Information System.

Europe Clinical Trials

EU Commission Again Delays Pharma Revision Proposals, Citing ‘Busy Agenda’

Two members of the European Parliament claim the latest delay to publication of the long-awaited legislative revision is the result of pressure from the pharmaceutical industry.

Europe Legislation

Upstaza: First Gene Therapy For Ultra-Rare Disorder AADC Deficiency Receives English Funding

The single-dose gene therapy for aromatic L-amino acid decarboxylase in children is to be made available on the National Health Service following a confidential commercial deal between NHS England and PTC Therapeutics.

Europe United Kingdom

UK’s Revamped Clinical Trials Framework To Offer Faster Application Review Timelines Than EU

The UK has finalized plans for delivering what it believes will be a stable and streamlined clinical trials framework following its departure from the EU. Transparency, patient involvement and diversity are high on the agenda.

United Kingdom Clinical Trials

Mixed Support For ABPI's UK Price Scheme Proposals

The UK pharma industry body has set out bold proposals for a new drug pricing agreement from 2024, but not everyone is convinced. Generics companies are pressing for more of a say in the negotiations, while patient groups want to know more about how the deal would help improve access to medicines.

Europe United Kingdom

Rare Disease Body Wants EU Legislative Overhaul To Address Orphan Definitions & Incentives

Eurordis has welcomed some parts of the leaked proposals for overhauling the EU medicines legislation, but it has a number of concerns, including the future role of patient representatives if the European Medicines Agency’s committee structure is slimmed down as planned.

Europe Rare Diseases

‘Gene Silencing’ Drug Oxlumo Wins English Funding After Alnylam Improves Discount

Health technology assessment institute NICE has reversed its provisional rejection of Oxlumo for treating the rare disease, primary hyperoxaluria type 1.

Europe Cost Effectiveness

New EU Filings

Sugemalimab, from CStone Pharmaceuticals/EQRx, for use in combination with chemotherapy as first-line treatment for metastatic non-small cell lung cancer, is among the latest drugs that have been filed for review by the European Medicines Agency for potential EU marketing approval.

Drug Review Europe
See All
UsernamePublicRestriction

Register